Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Short-Course malaria treatment could prevent relapses

NCT ID NCT05874271

Disease control Sponsor: Macfarlane Burnet Institute for Medical Research and Public Health Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 03, 2026 · Updated 3 times

Summary

This study tested a new approach to treat vivax malaria, a type that can hide in the liver and come back. Researchers used a quick test to check for a genetic condition (G6PD deficiency) that can cause dangerous side effects with the standard drug primaquine. Then, they gave a high-dose, short-course primaquine regimen tailored to each patient's G6PD level. The goal was to see if this strategy is safe, practical, and effective in preventing malaria relapse. The study involved 794 patients in Papua New Guinea.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
primaquine
What this could lead to
If successful, this approach could make radical cure of vivax malaria safer and more practical, reducing relapses and helping control the disease in affected regions.
What could go wrong
This is a feasibility study, not a large randomized trial, so results may not be definitive. The risk of hemolysis in G6PD-deficient patients remains a concern despite testing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

794 people

The number who actually took part.

Started

Aug 2023

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 months and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with vivax malaria Exclusion Criteria: * Patients who are pregnant * Patients who are breastfeeding * Patients with a Hb \<8g/dL * Patients with a previous adverse reaction to primaquine * Patient with severe malaria

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for G6PD deficiency are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

G6PD deficiency Plasmodium vivax malaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

G6PD deficiency Vivax malaria

Contacts and locations

Locations

  • Baro Clinic

    Vanimo, Sandaun Province, Papua New Guinea

  • Mugil Health Centre

    Madang, Madang Province, Papua New Guinea

  • Napapar Health Centre

    Kokopo, East New Britain Province, Papua New Guinea

  • Wirui Clinic

    Wewak, East Sepik Province, Papua New Guinea

More trials for these conditions

Other studies related to the condition(s) this trial covers.